Welcome to our dedicated page for SHRMF news (Ticker: SHRMF), a resource for investors and traders seeking the latest updates and insights on SHRMF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SHRMF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SHRMF's position in the market.
Braxia Scientific Corp. (CSE: BRAX, OTC: SHRMF, FWB: 496) announced a symbol change on the OTC Market from 'SHRMF' to 'BRAXF' effective May 21, 2021. The company focuses on developing ketamine treatments for depression and related disorders, emphasizing its commitment to setting standards in mental health care. Braxia operates multidisciplinary clinics in cities like Mississauga, Toronto, Ottawa, and Montreal, aiming to lead in ketamine and psychedelic treatment research.
Braxia Scientific Corp. (OTC: SHRMF) has launched the Braxia Institute, a center dedicated to advancing psychedelic and ketamine treatment for depression. The initiative aims to bridge the gap between clinical practices and neuroscience research, enhancing care quality for patients with mental health disorders. Over 200 physicians from Canada, the U.S., and Asia will attend the inaugural symposium on rapid-acting antidepressants, including ketamine and esketamine. CEO Dr. Roger McIntyre emphasizes the importance of translating research into effective clinical action.
Braxia Scientific Corp. (CSE: BRAX, OTC: SHRMF) has launched the Braxia Institute, a training center aimed at enhancing psychiatric practices related to rapid-acting anti-depressants like ketamine and esketamine. Over 200 healthcare providers from Canada, the U.S., and Asia attended the inaugural symposium focused on these innovative treatments. The Institute will bridge the gap between clinical practices and neuroscience research, ensuring the delivery of high-quality care for patients with treatment-resistant depression and other mental health disorders.
Braxia Scientific Corp. (OTC: SHRMF) announces the opening of its first privately owned ketamine therapy clinic in Quebec, in partnership with Neurotherapy Montreal. This joint venture aims to meet the region's significant mental health needs, as 20% of Quebec's population experiences mental illness. The clinic offers advanced treatments for depression, including intravenous ketamine therapy, in a state-of-the-art 14,000 sq. ft. facility. With over 3,000 treatments administered to date, Braxia is positioned to expand its reach in mental health services across Canada.
Braxia Scientific Corp. has rebranded its clinic network to Braxia Health and commenced trading under the new ticker CSE: BRAX. The network, established in 2018, is the only clinic in Canada involved in a pivotal trial for psilocybin treatment for depression. Led by Dr. Roger McIntyre, Braxia Health has become a leader in research and treatment for mental health disorders, focusing on rapid-acting therapies like ketamine. The company has administered over 3,000 treatments and plans to expand across North America and Europe.
Braxia Scientific Corp. has rebranded its clinic network to Braxia Health and commenced trading under the new ticker CSE: BRAX. The company aims to leverage its clinical research capabilities in the psychedelic treatment sector, particularly with ketamine and esketamine, targeted at mental health disorders such as treatment-resistant depression. The expansion will cover Canada, the U.S., and Europe, following significant achievements in outpatient treatment clinics across Canada since 2018.
Braxia Scientific Corp. (CSE: SHRM, OTCQB: SHRMF) announced that it has been served with a notice of civil claim for a proposed class action in British Columbia. The claim involves allegations related to the Company's disclosure concerning the value of four acquisitions made in 2020. The plaintiff seeks unspecified damages against the Company, its CEO, former officers, a shareholder, and underwriters from a private placement financing in June 2020. Braxia intends to vigorously defend its position.
Champignon Brands Inc. (CSE: SHRM, OTCQB: SHRMF) announced the revocation of cease trade orders by the British Columbia and Ontario Securities Commissions, effective April 22, 2021. Trading is set to resume on April 23, 2021. The cease trade orders were due to a content deficiency in a report from April 30, 2020, and a failure to provide periodic disclosure. The company is focused on developing rapid-acting treatments for depression and enhancing governance. It reduced its outstanding Common Shares from 177,290,212 to 167,510,212 through voluntary contributions from shareholders.
Champignon Brands Inc. has filed a new Listing Statement with the Canadian Securities Exchange, detailing its acquisition of AltMed Capital Corp. This transaction is a reverse takeover. Additionally, the company has requested the revocation of cease trade orders imposed by the British Columbia and Ontario Securities Commissions due to previous reporting deficiencies. Champignon has recently submitted updated financial statements covering several interim periods. The company focuses on innovative treatments for mental health disorders using ketamine and psilocybin derivatives.
